Omalizumab, an Anti-IgE mAb, Receives Approval for the Treatment of Chronic Idiopathic/Spontaneous Urticaria

Omalizumab, an anti-IgE mAb, has recently been approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of chronic idiopathic urticaria. Saini et al. (2014) (this issue) report on ASTERIA I, a 40-week randomized, double-blinded, placebo-controlled p...

Full description

Saved in:
Bibliographic Details
Published inJournal of investigative dermatology Vol. 135; no. 1; pp. 13 - 15
Main Authors Wu, Keith C.P., Jabbar-Lopez, Zarif K.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.01.2015
Elsevier Limited
Subjects
Anti-Allergic Agents - administration & dosage
Antibodies, Anti-Idiotypic - administration & dosage
Antibodies, Monoclonal, Humanized - administration & dosage
Asterias
Female
Histamine H1 Antagonists - administration & dosage
Humans
Male
Omalizumab
Urticaria - drug therapy
Online AccessGet full text

Cover

More Information
Summary:Omalizumab, an anti-IgE mAb, has recently been approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of chronic idiopathic urticaria. Saini et al. (2014) (this issue) report on ASTERIA I, a 40-week randomized, double-blinded, placebo-controlled phase III trial evaluating omalizumab for the treatment of this disease.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Commentary-1
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0022-202X
1523-1747
DOI:10.1038/jid.2014.362